Baxter International Inc. has acquired SuppreMol, a biopharma company based in Martinsried, Germany developing treatments for autoimmune and allergic diseases, for approximately $225 million. Baxter gains SuppreMol’s early-stage portfolio of novel biologic immunoregulatory therapeutics focusing on the modulation of Fc receptor signaling pathways, an immune target that could have broad applications in autoimmune disorders. Additionally, Baxter will continue to operate SuppreMol’s operations in Mu...